New drug LY3451838 tested in healthy people for safety
NCT ID NCT03692949
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested the safety and how the body handles a new drug called LY3451838 in 53 healthy adults. Participants received either a single dose of the drug into a vein or under the skin, or a placebo. The main goal was to check for side effects and measure drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LY3451838
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lilly Centre for Clinical Pharmacology
Singapore, 138623, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Which medical adhesive stays put longest without itching? a head-to-head test in healthy women.
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- New eye drop aims to tame ocular pain in early trial
- Could a formula closer to breast milk boost baby development?
- Could a daily probiotic help you feel fuller and eat less?